Carladenise Armbrister Edwards Sells 200,000 Shares of Clover Health Investments, Corp. (NASDAQ:CLOV) Stock

Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) Director Carladenise Armbrister Edwards sold 200,000 shares of Clover Health Investments stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $3.61, for a total value of $722,000.00. Following the sale, the director now owns 273,227 shares in the company, valued at $986,349.47. This trade represents a 42.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Clover Health Investments Stock Down 4.2 %

CLOV stock traded down $0.15 during trading on Thursday, hitting $3.46. The company had a trading volume of 5,618,524 shares, compared to its average volume of 6,472,544. Clover Health Investments, Corp. has a 1-year low of $0.61 and a 1-year high of $4.87. The firm has a 50-day moving average price of $4.11 and a 200-day moving average price of $3.62. The firm has a market cap of $1.77 billion, a PE ratio of -17.30 and a beta of 2.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Concurrent Investment Advisors LLC acquired a new position in Clover Health Investments in the 3rd quarter valued at $28,000. Sigma Planning Corp purchased a new stake in shares of Clover Health Investments in the third quarter valued at about $29,000. Parallax Volatility Advisers L.P. acquired a new stake in Clover Health Investments in the third quarter valued at about $38,000. Triumph Capital Management acquired a new position in Clover Health Investments during the fourth quarter worth $45,000. Finally, KBC Group NV purchased a new stake in shares of Clover Health Investments during the 3rd quarter worth $53,000. Institutional investors and hedge funds own 19.77% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CLOV shares. Canaccord Genuity Group increased their price objective on Clover Health Investments from $4.20 to $4.50 and gave the company a "buy" rating in a report on Monday, March 3rd. Craig Hallum initiated coverage on shares of Clover Health Investments in a research note on Tuesday, December 17th. They set a "buy" rating and a $6.00 price target for the company.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.